Crystalvue Medical Corporation (TPEX:6527)
Taiwan · Delayed Price · Currency is TWD 70.00
+0.90 (1.30%)
May 29, 2026, 1:30 PM CST
Crystalvue Medical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 912.86 | 949.05 | 868.03 | 823.96 | 795.46 | 721.61 | |
Revenue Growth (YoY) | 2.24% | 9.33% | 5.35% | 3.58% | 10.23% | 43.07% |
Cost of Revenue | 586.19 | 617.17 | 568.89 | 557.22 | 533.71 | 510.22 |
Gross Profit | 326.68 | 331.88 | 299.14 | 266.75 | 261.74 | 211.39 |
Selling, General & Admin | 109.6 | 110.68 | 108.48 | 104.4 | 89.97 | 73.73 |
Research & Development | 42.3 | 40.25 | 45.66 | 44.67 | 46.97 | 49.2 |
Operating Expenses | 151.9 | 150.93 | 154.14 | 149.07 | 136.94 | 122.93 |
Operating Income | 174.78 | 180.95 | 145.01 | 117.68 | 124.8 | 88.47 |
Interest Expense | -0.39 | -0.45 | -0.63 | -0.82 | -1 | -1.17 |
Interest & Investment Income | 2.13 | 2.23 | 2.14 | 1.47 | 0.47 | 1.06 |
Currency Exchange Gain (Loss) | -4.28 | -4.28 | 6.33 | 1.19 | 10.68 | -2.11 |
Other Non Operating Income (Expenses) | 0.88 | 0.3 | 6.53 | 0.22 | 7.48 | 8.97 |
EBT Excluding Unusual Items | 173.11 | 178.74 | 159.38 | 119.74 | 142.44 | 95.22 |
Gain (Loss) on Sale of Assets | 0.28 | 0.28 | - | - | - | 13.95 |
Pretax Income | 173.39 | 179.01 | 159.38 | 119.74 | 142.44 | 109.17 |
Income Tax Expense | 29.51 | 32.03 | 32.23 | 16.34 | 27.41 | 31.93 |
Net Income | 143.88 | 146.98 | 127.15 | 103.4 | 115.03 | 77.24 |
Net Income to Common | 143.88 | 146.98 | 127.15 | 103.4 | 115.03 | 77.24 |
Net Income Growth | 8.40% | 15.59% | 22.98% | -10.11% | 48.93% | 36.42% |
Shares Outstanding (Basic) | 25 | 25 | 25 | 25 | 25 | 25 |
Shares Outstanding (Diluted) | 25 | 26 | 26 | 25 | 26 | 25 |
Shares Change (YoY) | -2.89% | 0.30% | 1.64% | -0.91% | 0.53% | -0.99% |
EPS (Basic) | 5.86 | 5.80 | 5.02 | 4.13 | 4.59 | 3.08 |
EPS (Diluted) | 5.75 | 5.70 | 4.95 | 4.09 | 4.51 | 3.05 |
EPS Growth | 11.51% | 15.15% | 21.03% | -9.31% | 47.98% | 37.93% |
Free Cash Flow | -66.07 | -44.91 | 22.62 | 149.64 | 44.24 | -287.91 |
Free Cash Flow Per Share | -2.64 | -1.74 | 0.88 | 5.92 | 1.73 | -11.35 |
Dividend Per Share | 2.900 | 2.900 | 2.250 | 2.070 | 2.286 | 1.848 |
Dividend Growth | 28.89% | 28.89% | 8.70% | -9.44% | 23.71% | 38.57% |
Gross Margin | 35.79% | 34.97% | 34.46% | 32.37% | 32.91% | 29.29% |
Operating Margin | 19.15% | 19.07% | 16.71% | 14.28% | 15.69% | 12.26% |
Profit Margin | 15.76% | 15.49% | 14.65% | 12.55% | 14.46% | 10.70% |
Free Cash Flow Margin | -7.24% | -4.73% | 2.61% | 18.16% | 5.56% | -39.90% |
EBITDA | 181.49 | 190.33 | 165.75 | 139.51 | 143.92 | 122.55 |
EBITDA Margin | 19.88% | 20.05% | 19.10% | 16.93% | 18.09% | 16.98% |
D&A For EBITDA | 6.71 | 9.39 | 20.75 | 21.83 | 19.11 | 34.09 |
EBIT | 174.78 | 180.95 | 145.01 | 117.68 | 124.8 | 88.47 |
EBIT Margin | 19.15% | 19.07% | 16.71% | 14.28% | 15.69% | 12.26% |
Effective Tax Rate | 17.02% | 17.89% | 20.22% | 13.65% | 19.25% | 29.25% |
Advertising Expenses | - | - | - | - | - | 26.55 |